Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg for idiopathic small fiber neuropathy
2015-002624-31Phase 3Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2015
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small fiber neuropathy (SFN) comparing Gamunex with Placebo (2 arms). Primary endpoint: Primary objective pain endpoint. Started Nov 2015; status: terminated.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
small fiber neuropathy (SFN)
Beyond the preview
Go deeper on 2015-002624-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002624-31.